The multicomponent meningococcal serogroup B vaccine (4CMenB) : origin, composition, health impact and unknown aspects
Articolo
Data di Pubblicazione:
2015
Citazione:
The multicomponent meningococcal serogroup B vaccine (4CMenB) : origin, composition, health impact and unknown aspects / C. Mameli, E. Galli, C. Mantegazza, V. Fabiano, G. Zuccotti. - In: FUTURE MICROBIOLOGY. - ISSN 1746-0913. - 10:10(2015 Oct 10), pp. 1579-1598.
Abstract:
Neisseria meningitidis serogroup B is the main cause for meningococcal invasive disease in many parts of the world. Since 2013, a new multicomponent vaccine against meningococcal serogroup B (4CMenB) has been licensed in Europe, Australia, Canada, Chile, Uruguay, USA and Brazil with different immunization schedules. Clinical trials involving adults, adolescents, children and infants showed 4CMenB has a good immunogenicity and safety profile. Strain coverage estimates are similar to or better than other recently approved vaccines, ranging from 66% in Canada to 91% in Unites States. Some points still remain to be clarified such as the best immunization strategy, the effect of 4CMenB on carriage, the long-term persistence of protective bactericidal antibodies titers, long-term safety outcomes, the possible emergence of N. meningitidis escape mutants and the vaccine cost-effectiveness. In this review, we focus on the vaccine composition, clinical trials and suggested schedules, safety data, potential strain coverage and future challenges.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
4CMenB; immunogenicity; MATS; Neisseria meningitidis; reactogenicity; reverse vaccinology; vaccine
Elenco autori:
C. Mameli, E. Galli, C. Mantegazza, V. Fabiano, G. Zuccotti
Link alla scheda completa: